Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | THRA | P10827 | 5/20 | 0.58 |
| ▸ | THRB | P10828 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 3/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927630 | 1.00 | TRPV1 (0.64) | TRPV1NR1H4S1PR1L3MBTL1THRA | |
| SCHEMBL2186629 | 0.91 | TRPV1 (0.68) | TRPV1NR1H4S1PR1THRATHRB | |
| SCHEMBL3145220 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL3130654 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL9356282 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL9815969 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL10523939 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL3145641 | 0.88 | L3MBTL1 (0.76) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL3135443 | 0.87 | L3MBTL1 (0.78) | S1PR1L3MBTL1THRATHRBHAO1 | |
| SCHEMBL6931226 | 0.86 | TRPV1 (0.58) | TRPV1NR1H4S1PR1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | claimed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | TRPV1 2634/4885NR1H4 3620/4885S1PR1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.